论文信息 - LBA17RANDOMISED STUDY OF AXITINIB (AXI) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO (PBO) PLUS BSC IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING PRIOR ANTIANGIOGENIC THERAPY - 字舞流文

LBA17RANDOMISED STUDY OF AXITINIB (AXI) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO (PBO) PLUS BSC IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING PRIOR ANTIANGIOGENIC THERAPY

D. Chakrabarti | M. Kudo | T. Yau | R. Poon | S. Chan | S. Qin | O. Valota | S. Obi | E. Boucher | R. Kim | H. Lim | Y. Kang | J. Park | J. Tang | T-Y Lee